Quarterly ResultMay 15, 2026, 03:07 PM
Inhibitor Therapeutics Q1 Net Loss $0.7M; $3M financing in litigation, going concern
AI Summary
Inhibitor Therapeutics, Inc. reported a net loss of $0.7 million for Q1 2026, with negative cash flows from operations of $1.1 million. The company's cash and cash equivalents decreased significantly to $1.3 million. Management has issued a going concern warning due to insufficient liquidity to sustain operations for the next year. A critical $3.0 million financing deal is currently in litigation after the institutional investor failed to provide funds, further exacerbating liquidity concerns.
Key Highlights
- Net loss for Q1 2026 was $686,425, compared to $632,846 in Q1 2025.
- Cash and cash equivalents decreased to $1,290,978 as of March 31, 2026, from $2,375,493 at December 31, 2025.
- Negative cash flows from operating activities were $1,084,515 for Q1 2026.
- Research and development expenses increased to $340,562 in Q1 2026 from $236,058 in Q1 2025.
- General and administrative expenses were $355,070 in Q1 2026, down from $438,493 in Q1 2025.
- The company initiated litigation on March 30, 2026, over an institutional investor's failure to fund a $3.0 million securities purchase agreement.
- Total stockholders' deficit increased to $(1,978,337) as of March 31, 2026, from $(1,291,912) at December 31, 2025.
Price Impact
More from INTI